Because of the very low prevalence of BRCA1/2 germline mutation carriers among unselected breast cancer patients, the study was designed as a case-cohort study in order to acquire a reasonable number of BRCA1/2 tumors [47]. This evidence concerns the gene BRCA1 and breast carcinoma.